Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Impact of Chronic Kidney Disease on CYP3A4‐Mediated Metabolism of Saxagliptin

We characterized the impact of chronic kidney disease (CKD) on the cytochrome P450 (CYP) 3A4–mediated metabolism of saxagliptin to its metabolite, 5‐hydroxysaxagliptin, using a physiologically based pharmacokinetic (PBPK) model. A PBPK model of saxagliptin and its CYP3A4 metabolite, 5‐hydroxysaxagli...

Descripción completa

Detalles Bibliográficos
Autores principales: Butrovich, Morgan A., Tang, Weifeng, Boulton, David W., Nolin, Thomas D., Sharma, Pradeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Physiologically Based Pharmacokinetic Modeling
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545133/
https://www.ncbi.nlm.nih.gov/pubmed/35247279
http://dx.doi.org/10.1002/jcph.2043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545133/
https://www.ncbi.nlm.nih.gov/pubmed/35247279
http://dx.doi.org/10.1002/jcph.2043

Ejemplares similares